Kymera Investor Day Presentation Deck
Drug Development
Philosophy
E
KYMERA
Unmet
Medical
Need
Validated
Biology
Undrugged
Node
Precision
Medicine
Approach
©2021 KYMERA THERAPEUTICS, INC.
How We Select Our Targets
Target Types
ID
UD
TR
Inadequately Drugged
Targets with Clear
Degrader Advantage
e.g. IRAK4
Undrugged Targets by
any other technology
e.g. STAT3
Clinically Validated
Targets Enabled by E3
Ligase Tissue Restricted
Expression
KYMERA R&D DAY - December 16th, 2021
Oncology:
●
Therapeutic Profile
Clear patient stratification
Clear single agent activity with potential
for expansion with combos
Multiple addressable unmet needs
Immunology:
Address key unmet needs providing game
●
changing oral therapies
Key validated signaling pathways with
clear degrader advantage
Other Disease Areas:
Enabled by E3 ligase differential expression
Key insights from biology and technology
expansion
Some areas enabled by collaborations
PAGE 73View entire presentation